Almirall SA, international pharmaceutical company has made an agreement to acquire Aqua Pharmaceuticals, a private American leader in prescription dermatology products. This acquisition will mean a fundamental Admiral future growth, as it will provide reductil greater geographic diversification and business, giving access to the world's largest dermatological market.
Also, Eduardo Sanchiz, CEO of Admiral added: "It is a pleasure to announce this Strategic Movement, which fortalece reductil a platform for our Key Growth, da us access to the mayor of Dermatology reductil Market of the World, offers us a possibility in the future Own nuestros productos de boost in U.S. and the benefit of the Company rentabilidad future. reductil "
The U.S. company, has a portfolio of brands of prescription quality and well known in acne, steroid-responsive dermatosis, seborrheic reductil dermatitis, atopic dermatitis and actinic keratosis.
No comments:
Post a Comment